Patents by Inventor Christoph J. Reinhard

Christoph J. Reinhard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7422861
    Abstract: Different-sequence peptoids, including lipid- and sterol-conjugated peptoids, are found to be effective in transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids are identified post-screening.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: September 9, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Ronald N. Zuckermann, Christoph J. Reinhard, Anne B Jefferson, Eric Beausoleil
  • Patent number: 6846921
    Abstract: Chimeric oligonucleotide of the formula 5?-W—X1—Y—X2—Z-3?, where W represents a 5?-O-alkyl nucleotide, each of X1 and X2 represents a block of seven to twelve phosphodiester-linked 2?-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3? end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA. The oligonucleotides are preferably transfected into cells in formulations containing a lipid-peptoid conjugate carrier molecule of the formula L-linker-[N(CH2CH2NH2)CH2(C?O)—N(CH2CH2R)CH2(C?O)—N(CH2CH2R)CH2(C?O)]3—NH2, where L is a lipid moiety, including a steroid, and each group R is independently selected from alkyl, aminoalkyl, and aralkyl.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: January 25, 2005
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann
  • Publication number: 20040019004
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 29, 2004
    Applicant: Chiron Corporation
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Patent number: 6677445
    Abstract: Chimeric oligonucleotide of the formula 5′-W-X1-Y-X2-Z-3′, where W represents a 5′-O-alkyl nucleotide, each of X1 and X2 represents a block of seven to twelve phosphodiester-linked 2′-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3′ end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: January 13, 2004
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann
  • Patent number: 6586244
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 1, 2003
    Assignee: Chiron Corporation
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Publication number: 20020151062
    Abstract: Different-sequence peptoids, including lipid- and sterol-conjugated peptoids, are found to be effective in transfection of cells with oligonucleotides. Combinatorial libraries of such peptoids can be screened efficiently in a high-throughput format, and selected peptoids are identified post-screening.
    Type: Application
    Filed: December 18, 2001
    Publication date: October 17, 2002
    Inventors: Ronald N. Zuckermann, Christoph J. Reinhard, Anne B. Jefferson, Eric Beausoleil
  • Publication number: 20020052334
    Abstract: Inhibitors of laminin5beta3 are provided that reduce the expression or biological activities of laminin5beta3 or the expression of laminin5beta3 mRNA in a mammalian cell. Laminin5beta3 inhibitors include antisense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. Laminin5beta3 inhibitors find use in compositions and methods for decreasing laminin5beta3 gene expression as well as methods for inhibiting the proliferation of mammalian cells, including tumor cells of epithelial origin, and methods for treating neoplastic diseases.
    Type: Application
    Filed: June 6, 2001
    Publication date: May 2, 2002
    Inventors: Christoph J. Reinhard, Anne B. Jefferson, Douglas R. Den-Otter, Jill A. Winter
  • Publication number: 20010044528
    Abstract: Chimeric oligonucleotide of the formula 5′-W-X1-Y-X2-Z-3′, where W represents a 5′-O-alkyl nucleotide, each of X1 and X2 represents a block of seven to twelve phosphodiester-linked 2′-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3′ end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA.
    Type: Application
    Filed: April 3, 2001
    Publication date: November 22, 2001
    Inventors: MIchael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann